Sanofi Genzyme

Manufacturer of Libtayo (cemiplimab) the first FDA-approved therapy indicated for the treament of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.